OBJECTIVE: We examined whether the use of nonsteroidal antiinflammatory drugs (NSAIDs) in early pregnancy was associated with a range of structural birth defects. STUDY DESIGN: Data were from the National Birth Defects Prevention Study, a multisite population-based, case-control study of risk factors for birth defects. RESULTS: Among women in the National Birth Defects Prevention Study, 22.6% reported the use of NSAIDs in the first trimester of pregnancy, most commonly ibuprofen, aspirin, and naproxen. Of the 29 defect groups that were examined, most were not associated with NSAID use. Small-to-moderate increased risks of some oral cleft groups, some neural tube defect groups, anophthalmia/microphthalmia, pulmonary valve stenosis, amniotic bands/limb body wall defects, and transverse limb deficiencies were associated with ibuprofen, aspirin, and naproxen exposure. CONCLUSION: The use of NSAIDs in early pregnancy does not appear to be a major risk factor for birth defects, although there were a few moderate associations between NSAIDs and specific birth defects.
OBJECTIVE: We examined whether the use of nonsteroidal antiinflammatory drugs (NSAIDs) in early pregnancy was associated with a range of structural birth defects. STUDY DESIGN: Data were from the National Birth Defects Prevention Study, a multisite population-based, case-control study of risk factors for birth defects. RESULTS: Among women in the National Birth Defects Prevention Study, 22.6% reported the use of NSAIDs in the first trimester of pregnancy, most commonly ibuprofen, aspirin, and naproxen. Of the 29 defect groups that were examined, most were not associated with NSAID use. Small-to-moderate increased risks of some oral cleft groups, some neural tube defect groups, anophthalmia/microphthalmia, pulmonary valve stenosis, amniotic bands/limb body wall defects, and transverse limb deficiencies were associated with ibuprofen, aspirin, and naproxen exposure. CONCLUSION: The use of NSAIDs in early pregnancy does not appear to be a major risk factor for birth defects, although there were a few moderate associations between NSAIDs and specific birth defects.
Authors: Lorenzo D Botto; Angela E Lin; Tiffany Riehle-Colarusso; Sadia Malik; Adolfo Correa Journal: Birth Defects Res A Clin Mol Teratol Date: 2007-10
Authors: P W Yoon; S A Rasmussen; M C Lynberg; C A Moore; M Anderka; S L Carmichael; P Costa; C Druschel; C A Hobbs; P A Romitti; P H Langlois; L D Edmonds Journal: Public Health Rep Date: 2001 Impact factor: 2.792
Authors: Sonja A Rasmussen; Richard S Olney; Lewis B Holmes; Angela E Lin; Kim M Keppler-Noreuil; Cynthia A Moore Journal: Birth Defects Res A Clin Mol Teratol Date: 2003-03
Authors: Mary E Cogswell; Rebecca H Bitsko; Marlene Anderka; Alissa R Caton; Marcia L Feldkamp; Stacey M Hockett Sherlock; Robert E Meyer; Tunu Ramadhani; James M Robbins; Gary M Shaw; T J Mathews; Marjorie Royle; Jennita Reefhuis Journal: Am J Epidemiol Date: 2009-09-07 Impact factor: 4.897
Authors: Martha M Werler; Jane E Sheehan; Catherine Hayes; Allen A Mitchell; John B Mulliken Journal: Birth Defects Res A Clin Mol Teratol Date: 2004-06
Authors: Mario A Cleves; Van H Savell; Sarika Raj; Weizhi Zhao; Adolfo Correa; Martha M Werler; Charlotte A Hobbs Journal: Birth Defects Res A Clin Mol Teratol Date: 2004-03
Authors: Jennifer N Lind; Sarah C Tinker; Cheryl S Broussard; Jennita Reefhuis; Suzan L Carmichael; Margaret A Honein; Richard S Olney; Samantha E Parker; Martha M Werler Journal: Pharmacoepidemiol Drug Saf Date: 2013-04-26 Impact factor: 2.890
Authors: Dorothy Kim Waller; Syed Shahrukh Hashmi; Adrienne T Hoyt; Hao T Duong; Sarah C Tinker; Michael Shayne Gallaway; Richard S Olney; Richard H Finnell; Jacqueline Tauber Hecht; Mark A Canfield Journal: Birth Defects Res Date: 2017-11-02 Impact factor: 2.344
Authors: Yanqing Wu; E Albert Reece; Jianxiang Zhong; Daoyin Dong; Wei-Bin Shen; Christopher R Harman; Peixin Yang Journal: Am J Obstet Gynecol Date: 2016-03-31 Impact factor: 8.661